Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age - 09/08/11
Doi : 10.1016/j.jaad.2005.10.063
Lawrence F. Eichenfield, MD a, ⁎, B.H. Miller, MD b
on behalf of a Cutivate Lotion Study Group
a From the Children’s Hospital and Health Center-San Diego, University of California
b Oregon Medical Research Center
Reprint requests: Lawrence F. Eichenfield, MD, Pediatric and Adolescent Dermatology, Children’s Hospital and Health Center-San Diego, 8010 Frost St, Suite 602, San Diego, CA 92123.San Diego, California, and Portland, Oregon
Abstract |
A novel lotion formulation of fluticasone propionate 0.05% has recently become available. Two large, randomized, placebo-controlled, double-blind studies involving 438 subjects demonstrated its efficacy and safety when applied once daily in the treatment of atopic dermatitis in subjects from 3 months to 87 years of age. The studies were limited to 4 weeks duration of use of fluticasone lotion and did not assess longer term efficacy or side effects.
Le texte complet de cet article est disponible en PDF.Plan
| The study was sponsored by GlaxoSmithKline, NJ, USA. Cutivate is a trademark of the GSK group of companies. Funding sources: None. Conflicts of interest: None identified. |
© 2006
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 4
P. 715-717 - avril 2006 Retour au numéro
Article précédent
- Nail dystrophy and blisters as sole manifestations in myeloma-associated amyloidosis
- Yasuyuki Fujita, Yukiko Tsuji-Abe, Kazuko C. Sato-Matsumura, Masashi Akiyama, Hiroshi Shimizu
- Useful plants of dermatology. VIII. The false hellebore (Veratrum californicum)
- Marcus A. McFerren
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?